CD20-TCB (RG6026) is a novel 2:1 format T-cell engaging bispecific antibody. Here, Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the results of using this agent in relapsed/refractory B-cell lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.